Comparing the Effects of Three Different Dressings on the Cutaneous Response of Sacral Skin

NCT ID: NCT03815240

Last Updated: 2020-05-06

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

12 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-02-08

Study Completion Date

2019-07-23

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Skin functional parameters such as erythema or stratum corneum hydration have been successfully used in PU prevention research. These parameters are able to discriminate effects of different loading intensities and to measure PU preventive device performance.

The overall aim of this study is to measure the effects of Mepilex® Border Sacrum Dressing on the skin structure and function during mechanical loading compared to (1) no dressing, (2) ALLEVYN Life Sacrum Dressing and (3) Optifoam® Gentle Liquitrap Sacrum Dressing.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Pressure ulcers (PUs) are severe and unwanted cutaneous lesions and subcutaneous wounds caused by prolonged skin and underlying soft tissue deformation. In the supine position they predominantly occur near to bony prominences, like at the sacral area. The cornerstone of PU prevention is repositioning, early mobilization and the use of special support surfaces. In addition, empirical evidence suggests that the application of preventive dressings on PU predilection sites helps to prevent PU development.

Skin functional parameters such as erythema or stratum corneum hydration have been successfully used in PU prevention research. These parameters are able to discriminate effects of different loading intensities and to measure PU preventive device performance. Recently it could be shown that there are associations between structural and functional skin changes at the sacral area during loading. The overall aim of this study is to measure the effects of Mepilex® Border Sacrum Dressing on the skin structure and function during mechanical loading compared to no dressing, ALLEVYN Life Sacrum and Optifoam® Gentle Liquitrap Sacrum.

The procedure of one visit will be as follows:

After a skin acclimatization time of 30 minutes baseline measurements and Cyanoacrylate Skin Surface (CSSS)-stripping will be performed. Then a randomization envelope will be opened and the corresponding dressing will be applied or the skin will be left uncovered. The subject will then lie in supine position on a standard hospital mattress for a loading period of 3.5 hours. Every 30 minutes the head of the bed will be elevated to 45° for five minutes. During these five minutes, the participants will be instructed to bend their knees and to drag the feet repeatedly forth and back 10 times in order to simulate shear forces. The whole exercise will be done six times, after 0.5, 1, 1.5, 2, 2.5 and 3 hours. After 3.5 hours loading time in supine position the subjects will move into prone position. The dressing (if present) will be removed and all skin measurements and CSSS-stripping will be conducted again. The subjects will come back for another three times completing the remaining interventions. At the end, each volunteer will have received all three types of dressings once and once no dressing. In between, there are at least 3 weeks to prevent possible carry over effects.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pressure Ulcer Prevention

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

no dressing (A)

No dressing will be applied at sacrum before 3.5 hours loading period in supine position

Group Type OTHER

No dressing

Intervention Type OTHER

no dressing at sacrum

Mepilex (B)

'Mepilex® Border Sacrum' dressing will be applied at sacrum before 3.5 hours loading period in supine position

Group Type ACTIVE_COMPARATOR

Mepilex® Border Sacrum

Intervention Type OTHER

adhesive sacrum dressing

Allevyn (C)

'ALLEVYN Life Sacrum' dressing will be applied at sacrum before 3.5 hours loading period in supine position

Group Type ACTIVE_COMPARATOR

ALLEVYN Life Sacrum

Intervention Type OTHER

adhesive sacrum dressing

Optifaom (D)

'Optifoam® Gentle Sacrum' Dressing will be applied at sacrum before 3.5 hours loading period in supine position

Group Type ACTIVE_COMPARATOR

Optifoam® Gentle Sacrum

Intervention Type OTHER

adhesive sacrum dressing

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

No dressing

no dressing at sacrum

Intervention Type OTHER

Mepilex® Border Sacrum

adhesive sacrum dressing

Intervention Type OTHER

ALLEVYN Life Sacrum

adhesive sacrum dressing

Intervention Type OTHER

Optifoam® Gentle Sacrum

adhesive sacrum dressing

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy female volunteers
* 65 to 80 years
* Body Mass Index 18.5 to 29.9 kg/m2
* Non-smoker of at least one year (including electronic-cigarettes)
* Informed consent
* Being free of any clinical dermatosis in the investigational area
* Intact sacral skin without scars
* Skin phototype I, II, or III (according to Fitzpatrick)
* No regular use of leave-on products on the sacral skin
* Willing and able to fulfil the study requirements

Exclusion Criteria

* Disability to maintain in supine or prone Position
* Acute diseases
* Known hyper-sensibility or allergy to the study product or any of its ingredients
* Extensive UV exposure 4 weeks before study inclusion
* Use of topical treatment on the investigational areas or systemic Treatment within the 4 past weeks (topical hyaluronan, anti-inflammatory drugs, corticoids, retinoids, NSIDS etc.) that would interfere with assessment and/or investigational treatments
* Medical history of skin cancer
* History of established Diabetes mellitus, cardiac or renal insufficiency, COPD
* Chronic inflammatory skin disorders such as atopic dermatitis, psoriasis, lichen planus
* Participation in another study 4 weeks prior to study start
Minimum Eligible Age

65 Years

Maximum Eligible Age

80 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Charite University, Berlin, Germany

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

PD Dr. Jan Kottner

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Charité-Universitätsmedizin Berlin

Berlin, , Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CRC-SP-A-32

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.